{"transactions":[{"id":2647082,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":68370,"kind":"person","name":"Peng George","position":1,"cik":"0001651293","reported_name":"Peng George","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former officer"}}],"security":"Warrants","published_at":"2021-07-01T19:54:47.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":15000,"price":1,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination."}],"balance_after":15000,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-21-015903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651293/000149315221015903/ownership.xml","form_type":"4"}},{"id":4097413,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":68370,"kind":"person","name":"Peng George","position":1,"cik":"0001651293","reported_name":"Peng George","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-17T17:26:44.000Z","date":"2018-01-15","kind":"other","acquired":false,"shares":13251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 13,251 shares held by Mr. Peng were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 13,251 shares held by Mr. Peng were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."}],"balance_after":87014,"source":{"system":"sec-edgar","filing":"0001615774-18-000386","document":"s108740_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651293/000161577418000386/s108740_form4.xml","form_type":"4"}},{"id":4141375,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":68370,"kind":"person","name":"Peng George","position":1,"cik":"0001651293","reported_name":"Peng George","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-12-05T18:55:56.000Z","date":"2017-12-05","kind":"other","acquired":false,"shares":733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 733 shares held by Mr. Peng were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 733 shares held by Mr. Peng were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 13,251 shares held by Mr. Peng that are subject to forfeiture to the extent that the underwriters' overallotment option in the Company's initial public offering is not fully exercised."}],"balance_after":100265,"source":{"system":"sec-edgar","filing":"0001144204-17-062468","document":"tv480818_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651293/000114420417062468/tv480818_4.xml","form_type":"4"}}]}